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Thirteen years ago, human cyclin T1 was identified as part of the positive transcription elongation factor
b (P-TEFb) and the long-sought host cofactor for the HIV-1 transactivator Tat. Recent years have brought
new insights into the intricate regulation of P-TEFb function and its relationship with Tat, revealing novel
mechanisms for controlling HIV transcription and fueling new efforts to overcome the barrier of transcrip-
tional latency in eradicating HIV. Moreover, the improved understanding of HIV and Tat forms a basis for
studying transcription elongation control in general. Here, we review advances in HIV transcription research
with a focus on the growing family of cellular P-TEFb complexes, structural insights into the interactions
between Tat, P-TEFb, and TAR RNA, and the multifaceted regulation of these interactions by posttranscrip-
tional modifications of Tat.Introduction
HIV-1 transcription is a critical step in the viral life cycle (Peterlin
and Price, 2006). After entering CD4+ lymphocytes or macro-
phages, the viral RNA genome is reverse transcribed, and the
HIV provirus is integrated into the host chromatin where it
becomes subject to transcription by host RNA polymerase II
(Pol II). At this stage, HIV transcription encounters a unique
problem: while the host Pol II complex initiates transcription
successfully, it fails to travel far on the viral template. The result-
ing short viral transcripts cannot support viral replication (Kao
et al., 1987). To overcome this restriction, HIV-1 encodes an
essential accessory protein, the transcriptional transactivator
Tat, which does not act alone. The human positive transcription
elongation factor b (P-TEFb) is an essential human cofactor for
Tat transactivation (Mancebo et al., 1997; Wei et al., 1998; Zhu
et al., 1997).
P-TEFb consists of the cyclin-dependent kinase 9 (CDK9) and
its regulatory partner cyclin T (CycT), which has three forms:
CycT1, CycT2a, and CycT2b. P-TEFb phosphorylates serines
at the second position (Ser2) within each of the heptapeptide
repeats that constitute the C-terminal domain (CTD) of the
largest subunit of Pol II. The phosphorylated CTD serves as
a platform for the assembly and operation of a variety of
transcription and RNA processing factors that modulate tran-
scriptional elongation, termination, and cotranscriptional pro-
cessing of pre-mRNAs (Peterlin and Price, 2006). Besides the
CTD, P-TEFb also phosphorylates the negative elongation
factors DSIF and NELF to antagonize their inhibitory actions,
triggering the release of Pol II from promoter-proximal
pausing (Figure 1A). Recently, histone H1 was also found to be
phosphorylated by P-TEFb, representing another process that
promotes cellular and HIV transcription and is modulated by
Tat (O’Brien et al., 2010).
In recent years, the crucial role of transcription elongation
control has expanded from HIV to many rapidly induced cellular
genes involved in development and cellular activation/differenti-426 Cell Host & Microbe 10, November 17, 2011 ª2011 Elsevier Inc.ation (Levine, 2011). It is now apparent that P-TEFb activity is
tightly controlled in cells and that Tat employs distinctive mech-
anisms to usurp P-TEFb activity for HIV replication. Here, we
review recent advances in our understanding of HIV transcription
elongation control with a focus on the regulation of Tat and
P-TEFb activities. These advances are critical to ongoing efforts
to overcome HIV proviral latency, a process associated with
transcriptional silencing of the HIV provirus, and to ultimately
eradicate HIV from infected people.
The Tat/TAR Axis Is Central to Viral Transactivation
During HIV-1 transcription elongation, Tat binds to the transacti-
vation response (TAR) element, a highly conserved RNA stem-
loop structure that forms spontaneously at the 50 ends of nascent
viral transcripts. During this process, Tat cooperatively binds
human CycT1, but cannot interact with the related CycT2a or
CycT2b proteins. As a result, P-TEFb complexes containing
CycT1 are recruited to the loop region of TAR, where CDK9
and potentially other members of the P-TEFb elongation
complex are positioned next to the paused Pol II complex
(Figure 1A). Upon phosphorylation by CDK9, Pol II is released
from pausing, resumes elongation, and produces the full-length
HIV-1 transcripts that are required for productive viral replication
(Peterlin and Price, 2006). Importantly, Tat production itself
depends on successful transcription elongation, and the positive
feed-forward loop mediated by Tat and P-TEFb is essential for
productive HIV-1 replication (Razooky and Weinberger, 2011).
Despite its small size (8–11 kDa), Tat contains several critical
functional regions that are conserved in lentiviridae fromdifferent
species (Figure 1B). A variable sequence of 20–50 residues at the
N terminus of Tat precedes a characteristic cysteine-rich
segment that contains up to seven cysteines and one histidine
within 16 amino acids (aa 22–37 in HIV-1 Tat). C-terminal to the
cysteine-rich segment is the core region, which has the highest
sequence conservation among Tat proteins. The N-terminal,
cysteine-rich, and core regions of Tat form the so-called
AB
Figure 1. Function and Sequences of
Lentiviral Tat Proteins
(A) HIV-1 Tat recruits the CycT1/CDK9 core
complex and potentially other P-TEFb-interacting
proteins to the TAR RNA element and activates
transcription elongation through phosphorylating
RNA polymerase II CTD and negative elongation
factors DSIF and NELF.
(B) Sequence alignment of lentiviral Tat proteins.
Posttranslational modifications are indicated for
HIV-1 Tat. Ac, acetyl; Me, methyl; Ub, ubiquitin.
Cell Host & Microbe
Reviewtransactivation domain, which is primarily involved in P-TEFb
binding. The neighboring arginine-rich motif (ARM, aa 49–57 in
HIV-1 Tat) is essential for regulating TAR RNA binding, nuclear
localization, and stability of Tat. Many posttranslational modifi-
cations in Tat are clustered in the Tat ARM (described below).
The amino acid sequence C-terminal to the ARM is variable
and contains up to 50 additional residues in the longest splicing
variant of HIV-1 Tat, but exhibits some loosely conserved hydro-
phobic residues (labeled as a leucine motif in Figure 1B).
Tat proteins from all lentiviridae bind specific TAR RNA
elements. The HIV-1 TAR RNA element comprises nucleo-
tides +19 to +43 as the minimal responsive element that is
both necessary and sufficient for Tat binding in vivo and
in vitro. It contains a six-nucleotide hairpin loop and a three-
nucleotide pyrimidine-rich bulge (UCU) in the stem region four
nucleotide pairs away from the loop. The compositions of the
bulge and of the nucleotide pairs that form the RNA double
strand vary substantially between different lentivirus species.
HIV-2 and the bovine Jembrana disease virus (JDV) contain
two-nucleotide bulges (UU and AU, respectively), while the
bovine immunodeficiency-like virus (BIV) has two single U
inserts, and TAR from equine infectious anemia virus (EIAV) lacks
a bulge structure all together. Tat proteins from different lenti-
virus species coevolved with their respective TAR RNA
elements, as the size of the bulge in TAR RNA is inversely corre-
lated to the length of the spacer connecting the core region with
the ARM element in Tat (Anand et al., 2008).
The Structure of the Core P-TEFb Complex
The first breakthrough in resolving the Tat/TAR/P-TEFb structure
came from determining a CDK9/CycT1 complex structure. ThisCell Host & Microbe 10, Nwas accomplished with a truncation
variant of CycT1 that contains only the
two N-terminal cyclin box repeats and
their characteristic flanking helices
(Baumli et al., 2008). While this structure
shows good overall similarity to struc-
tures previously obtained from cell-cycle
CDK/Cyclin pairs, distinct differences
were observed in the relative orientation
of the subunits to each other. Overall,
the interaction interface area of P-TEFb
is40% smaller than that of CDK2/Cyclin
A. The C-terminal helix flanking the cyclin
box repeats shows increased flexibility in
the P-TEFb structure compared to other
CDK/Cyclin pairs. In addition, a mecha-nism of autophosphorylation for the catalytic Thr186 in the acti-
vation segment, the so-called T loop present in all CDK enzymes,
as well as three C-terminal phosphorylation sites in CDK9 was
attributed to the CDK9/CycT1 complex (Baumli et al., 2008).
While the phosphorylation of the T loop is known to activate
the catalytic activity of CDK enzymes, the function of the three
C-terminal phosphorylation sites in CDK9 with respect to
substrate-modifying activity remains to be investigated.
The seven cysteines present within the 16-aa cysteine-rich
region of Tat have been a major obstacle to obtaining a three-
dimensional Tat structure. They can cause transient disulfide
and zinc finger formations of high variability in recombinant
protein expressed for structural studies. One solution to this
problem was recently presented by Tahirov et al. (Tahirov
et al., 2010). In this study, an 86-aa recombinant Tat protein
was used, of which the N-terminal 49 residues were resolved
in the crystal structure. Tat is considered an intrinsically unfolded
protein that requires binding partners for proper folding (Shojania
andO’Neil, 2006).When bound to P-TEFb, Tat adopts a structure
that is complementary to the surface of P-TEFbandburies a large
interaction area. The N-terminal part of Tat assembles mainly in
the cleft between the first and second cyclin box repeat of
CycT1, but surprisingly, the CDK9 T-loop is also partially
involved in binding (Figure 2A). Cys22, Cys34, and Cys37,
together with His33, form an intramolecular zinc finger within
Tat, whereas the intermolecular zinc finger to Cys261 of CycT1
is mediated by Cys25, Cys27, and Cys30 of Tat (Figure 2A).
However, since these cysteines of HIV-1 Tat are not conserved
in Tat proteins across species, and the segment between the
last visible residue in the structure of CycT1, Lys252, and the
proposed position where C261 has been placed in the zinc fingerovember 17, 2011 ª2011 Elsevier Inc. 427
Figure 2. Crystal Structures of Tat
Transcription Complexes
(A) Crystal structure of the HIV-1 Tat/CDK9/CycT1
complex (PDB accession code 3MIA) (Tahirov
et al., 2010). The two zinc finger assemblies are
shown as stick representations. The position of the
catalytic phospho-Thr186 in the T-loop of CDK9 is
indicated.
(B) Crystal structure of the EIAV Tat/TAR/CycT1
complex (2W2H) (Anand et al., 2008). The N- and
C-terminal regions of Tat merge at the position of
a tyrosine residue in the core region of Tat.
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also be explained by an artificial contact to the noncleavable
hexahistidine affinity tag of a neighboring CDK9 molecule, which
could have resulted from crystal packing.
First Insights into the Structure of Tat/TAR/P-TEFb
Although no crystal structure exists for the HIV-1 Tat/TAR/P-
TEFb complex, a recent crystal structure of the tripartite ribonu-
cleoprotein complex formed by EIAV Tat/TAR and its corre-
sponding equine CycT1 gives some valuable insights (Anand
et al., 2008). Here, the C-terminal part of EIAV Tat, including
the ARM, was resolved (aa 41–69), and the bound 22-mer TAR
RNA was well visible (Figure 2B). The C-terminal part of Tat is
wound on the structure of CycT1, a process that seems to stabi-
lize Tat and contribute to the binding specificity. The core motif
and the C-terminal hydrophobic moiety of Tat are suspended
on the first cyclin box repeat of CycT1 so the helical ARM, which
lies in between, is largely exposed for RNA binding.
The ARM of EIAV Tat binds to the major groove of TAR RNA. A
tight tripartite complex formation is observed with equine CycT1
in the RNA hairpin loop. The fifth nucleotide within the RNA loop
section contributes significantly to the specificity of the interac-
tion by directly contacting CycT1 (Anand et al., 2008). As EIAV
TAR adopts a stable 6-mer hairpin loop when bound to the
Tat/CycT1 complex, similar to HIV-1 TAR, the modeling of the
UCU bulge of HIV-1 TAR into the tripartite EIAV Tat/TAR/
CycT1 complex is possible. Here, the bulge in HIV TAR comes
close to the Tat recognition motif in CycT1. At the same time,
the linker connecting the core region with the ARM in HIV-1 Tat
is four residues shorter than that of EIAV Tat, explaining the
species-specific binding characteristics observed for the two
lentiviral Tat/TAR pairs. Interactions of the basic ARM in Tat
are mostly electrostatic in nature and directed, in part, to the
phosphate backbone of the 50 strand in TAR. These electrostatic
interactions are thus not specific to the base pair compositions
formed in the various TAR species and probably highly sensitive
to posttranslational modifications of Tat (i.e., acetylation) that
invoke the charge necessary to prime the recognition.
Posttranslational Modifications Regulate Tat
Transcriptional Activity
Tat and P-TEFb are subject to multiple posttranslational modifi-
cations, many of which alter the critical interaction of these two428 Cell Host & Microbe 10, November 17, 2011 ª2011 Elsevier Inc.factors with TAR RNA. None of the modi-
fications have yet been examined struc-
turally. As posttranslational modificationsof P-TEFb were recently reviewed elsewhere (Cho et al., 2010),
we focus here onmodifications in Tat. As posttranslational modi-
fications are often transient and reversible in nature, they allow
rapid fine-tuning of Tat function during the HIV transcription
cycle (Figure 3). Strikingly, many of the enzymes that modify
Tat also modify histones, thus linking the transcriptional activity
of Tat to the transcriptional status of the integrated and chroma-
tinized HIV provirus.
Many modifications are found in the ARM region of Tat, under-
scoring the central role of this region in mediating interactions
with TAR RNA and CycT1. Tat modifications can be divided
into inhibitory and activating ones.
Modifications that Turn Tat Off
Inhibitory modifications include arginine methylation by the
methyltransferase PRMT6 and lysine methylation by SETDB1
(recently renamed to KMT1E) (Figure 3). PRMT6 is a nuclear
type I PRMT that monomethylates and asymmetrically dimethy-
lates arginines (Frankel et al., 2002). Remarkably, three of the
known substrates of this enzyme are HIV-1 proteins, including
Tat, Rev, and nucleocapsid (Boulanger et al., 2005; Invernizzi
et al., 2006, 2007). Methylation sites have been mapped to
Arg52 and Arg53 within the Tat ARM, and the methylation inter-
feres with formation of the Tat/TAR/P-TEFb complex, thereby in-
hibiting Tat function (Xie et al., 2007).
A similar effect was attributed to the methylation of the neigh-
boring Lys50 and Lys51 by SETDB1 (Van Duyne et al., 2008).
SETDB1 di- or trimethylates lysine residues and was originally
identified as a transcriptional silencer by methylating Lys9 in
histone H3 (Schultz et al., 2002). Notably, unlike acetylation,
methylation does not neutralize the positive charge of the
lysine or arginine. It is unclear at this point how methyl groups
at Lys50, Lys51, Arg52, and Arg53 in Tat interfere with TAR
and P-TEFb binding, but they might sterically hinder a tight inter-
action with nucleotides in the hairpin loop of TAR (Anand et al.,
2008).
It is also unclear if these inhibitorymethylation events in Tat are
reversible or if they mark a stable pool of transcriptionally inac-
tive Tat in infected cells (i.e., destined for other nontranscrip-
tional functions of Tat). These modifications have been sug-
gested to specifically inactivate Tat in latently infected cells,
thereby contributing to the transcriptionally inactive status of
the latent HIV provirus. Interestingly, arginine methylation was
linked to enhanced Tat stability, supporting a model where the
Figure 3. Regulation of Tat Function by Posttranslational Modifications
Inhibitory and activatory Tat posttranslational modifications regulate the association of Tat with TAR RNA and P-TEFb during different steps of the Tat trans-
activation cycle.
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cells (Sivakumaran et al., 2009).
Modifications that Turn Tat On
Activating modifications span Tat from NTDs to CTDs and
include phosphorylation, polyubiquitination, acetylation, and
monomethylation. Notably, the first modification found in Tat
was phosphorylation by the Tat-associated kinase, now known
to be P-TEFb. However, this modification was only observed in
HIV-2 Tat (Herrmann and Rice, 1993). HIV-1 Tat is phosphory-
lated by the interferon-induced, double-stranded, RNA-depen-
dent serine/threonine protein kinase, PKR, and the cell-cycle-
dependent kinase CDK2/cyclin E complex. Both modifications
stimulate Tat transcriptional activity (Ammosova et al., 2006;
Endo-Munoz et al., 2005). However, the larger role of Tat phos-
phorylation in HIV-1 infection remains unclear.
Although polyubiquitination classically marks proteins for
degradation by the proteasome, ubiquitin has a nonproteolytic
and activating effect on Tat (Bre`s et al., 2003). Polyubiquitination
of Tat is mediated by the proto-oncoprotein Hdm2 (Bre`s et al.,
2003). Lys71 in the CTD of HIV-1 Tat serves as the major,
although probably not the only, ubiquitination site in Tat. Strik-
ingly, Lys71 is highly conserved in HIV-1 isolates, but not in other
lentiviral Tat proteins (Figure 1B). How ubiquitination of TatCeaffects its transcriptional activity is not clear. However,
enhanced binding to CycT1 has been identified as one mecha-
nism of ubiquitin-mediated transcriptional activation by the
herpesvirus VP16 transactivator (Kurosu and Peterlin, 2004).
No effect of Lys71 mutation or ubiquitination by Hdm2 on the
overall half-life of Tat has been found. Interestingly, Tat itself
interacts with a proteasome-associated protein, PAAF1, and
shifts proteasome function to a nonproteolytic mode (Lassot
et al., 2007). How this novel function is linked to Lys71 ubiq-
uitination in Tat remains to be further explored.
Another well-studied activating modification is the acetylation
of Lys28 located in the cysteine-rich region of HIV-1 Tat (Kiernan
et al., 1999). This modification is critical for high-affinity binding
of Tat to TAR and P-TEFb (Bre`s et al., 2002). Lys28 is acetylated
by the acetyltransferase PCAF/KAT2B in vitro, but the cysteines
surrounding Lys28 via their reactive sulfhydryl groups also serve
as spontaneous acetyl acceptors, promoting the acetylation of
Tat in the absence of an enzyme (Dormeyer et al., 2003). In the
absence of P-TEFb and Lys28 acetylation, bovine lentivirus Tat
proteins have evolved alternative mechanisms of TAR binding
(D’Orso and Frankel, 2009).
Acetylation of Lys28 is reversed by the action of histone
deacetylase 6 (HDAC6) (Huo et al., 2011b). HDAC6 is a mainlyll Host & Microbe 10, November 17, 2011 ª2011 Elsevier Inc. 429
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cells (Hubbert et al., 2002). Indeed, association of HDAC6 and
Tat is microtubule dependent, pointing to possible extranuclear
functions of Lys28-acetylated Tat in conjunction with microtubu-
lin (Chen et al., 2002; Huo et al., 2011a). Alternatively, HDAC6
may deacetylate Tat in the nucleus and trigger the export of
Tat to the cytoplasm, explaining the observed inhibitory role of
HDAC6 on Tat transcriptional activity.
The ‘‘Yin and Yang’’ of Tat Modifications
A fourth activation marker of Tat is the monomethylation of
its ARM region. Here, Lys51 is targeted by the monomethyl-
transferase Set7/9 (renamed KMT7) (Pagans et al., 2010). The
fact that Lys51 is subject to inhibitory and activating
modifications points to a central role of this residue in the Tat
transactivation cycle. This role is supported by structural data
from the EIAV Tat/TAR/CycT1 complex (Anand et al., 2008).
Extrapolation of this structure to HIV-1 Tat indicates that
Lys51 plays a central role in the interaction with bases of
the first Watson-Crick base pairings proximal to the hairpin
loop of TAR RNA. Di- or trimethylation of this residue may inter-
fere with this interaction, while monomethylation strengthens
the complex formation between Tat, TAR, and CycT1 (Pagans
et al., 2010). Interestingly, Set7/9 itself possesses weak TAR
RNA binding activity that requires both bulge and loop struc-
tures in TAR.
Like acetylation, monomethylation of Lys51 is also a highly
dynamic process and reversed by the action of the lysine-
specific demethylase LSD1 (renamed KDM1) (Sakane et al.,
2011). LSD1 and its cofactor CoREST normally form a well-char-
acterized corepressor complex by removing the activating
histone mark at Lys4 in histone H3 (Shi et al., 2005). However,
in the context of Tat, both activate HIV gene transcription
through demethylation of Lys51 by LSD1. A similar activator
function of LSD1 was recently uncovered in a-herpesvirus lytic
replication and reactivation from latency (Liang et al., 2009).
Similarly, LSD1 and CoREST are necessary for full reactivation
of latent HIV, a finding that opens therapeutic opportunities for
using small-molecule inhibitors of LSD1 in the pharmacological
enforcement of HIV latency.
At first sight, it is surprising that both monomethylation and
demethylation of Tat are required for Tat transcriptional activity.
However, Tat transactivation is likely a multistep process in
which early TAR-dependent activating steps are followed by
late TAR-independent steps that appear equally important to
support full Tat function, but are less well defined. One striking
finding is that Tat binds directly to the Pol II complex (Cujec
et al., 1997). This observation supports a model in which Tat
translocates from the TAR element directly onto the elongating
polymerase complex during transcript elongation. The switch
between TAR-dependent and TAR-independent phases of Tat
function is likely mediated by yet another well-characterized
modification of Tat, the acetylation of Lys50 and also Lys51,
both located in the Tat ARM.
Dynamic Acetylation and Deacetylation of the Tat ARM
Two enzymes acetylate Lys50 and Lys51 in HIV-1 Tat: p300/CBP
(renamed KAT3B) and human GCN5/KAT2A, a close homolog of
PCAF/KAT2B (Col et al., 2001; Kiernan et al., 1999; Ott et al.,
1999). As alluded to above, neutralizing the charge in the highly
basic Tat ARM is expected to obviate the electrostatic interac-430 Cell Host & Microbe 10, November 17, 2011 ª2011 Elsevier Inc.tions between Tat and TAR (Figure 2B). Indeed, acetylation of
Lys50 dissociates Tat from TAR RNA and P-TEFb, probably
terminating the TAR-dependent phase of Tat transactivation.
This step appears critical, as neutralizing antibodies targeting
acetylated Lys50 in cells suppress Tat transactivation (Kaehlcke
et al., 2003). Lys50 acetylation also generates a new binding
interface in Tat for chromatin-modifying transcriptional coactiva-
tors, such as the histone acetyltransferase PCAF/KAT2B and
yet unknown members of the SWI-SNF chromatin-remodeling
complex (Bre`s et al., 2002; Dorr et al., 2002; Mahmoudi et al.,
2006). PCAF/KAT2B contains a specialized protein domain
called bromodomain that interacts with acetylated lysines
(Dhalluin et al., 1999). The NMR structure of a Lys50-acetylated
Tat peptide and the PCAF/KAT2B bromodomain revealed how
acetylated Lys50 and additional amino acids surrounding
Lys50 in the ARM enhance recruitment of the cofactor to Tat
(Mujtaba et al., 2002).
Tat acetylation is highly reversible by the action of the class III
deacetylase sirtuin 1 (SIRT1), a versatile protein deacetylase
connected with life span control (Pagans et al., 2005). SIRT1
function is regulated by its essential cofactor NAD+, coupling
Tat function to themetabolic state of infected cells. Similar to de-
methylation of Lys51, Tat deacetylation by SIRT1 is required for
full Tat transactivation (Pagans et al., 2005). The possibility exists
that Tat deacetylation occurs at the end of the transcription cycle
and serves to recycle acetylated Tat to the nonacetylated form,
which forms the complex with TAR RNA and P-TEFb. Interest-
ingly, in the context of a latent HIV provirus, SIRT1 inhibits Tat
transactivation, raising the possibility that the functions of
SIRT1 and the flow of Tat posttranslational modifications may
differ in actively and latently infected cells (Weinberger et al.,
2008).
Control of P-TEFb Expression and Activity
in Immune Cells
Because P-TEFb is a potent transcription factor essential
for Tat function and expression of numerous cellular genes
(Chao and Price, 2001; Rahl et al., 2010), its activity is tightly
regulated under normal conditions. In CD4+ T lymphocytes and
monocytes, translation of CycT1 mRNA is actively repressed
(Rice and Herrmann, 2003). During T cell activation or monocyte
differentiation into macrophages, protein but not mRNA levels of
CycT1 are upregulated, which correlates with enhanced permis-
siveness of these cells to HIV-1 infection (Rice and Herrmann,
2003). In monocytes, a microRNA (miR-198) represses CycT1
mRNA translation and HIV-1 replication, but in resting CD4+
T cells, the posttranscriptional mechanism controlling CycT1
expression is still unknown (Sung and Rice, 2009). However,
restricted supply of P-TEFb contributes to viral latency in primary
T cells (Tyagi et al., 2010).
In addition, in resting T cells or undifferentiated monocytes,
phosphorylation of the CDK9 T loop is barely detectable,
while it is rapidly induced upon T cell activation and monocyte
differentiation (Ramakrishnan et al., 2009). Besides autophos-
phorylation, the precisemechanism responsible for T-loop phos-
phorylation in CDK9 remains unknown, but calcium/calmodulin-
dependent kinase 1D and Csk1 are candidate kinases in HeLa
cells and in fission yeast, respectively (Pei et al., 2006; Ramak-
rishnan and Rice, 2011).
Figure 4. Differential Recruitment of P-TEFb
from the 7SK snRNP during HIV Infection
The 7SK snRNP is a cellular reservoir of inactive
P-TEFb that contains Hexim1, an inhibitor of the
CDK9 kinase activity. It is targeted by the HIV-1 Tat
protein to recruit active P-TEFb for transactivation
of HIV-1 transcription or is disrupted upon expo-
sure of cells to hypertrophic or stress signals to
release active P-TEFb associated with bromodo-
main-containing protein 4 (Brd4) to induce basal
HIV transcription in the absence of Tat.
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A Reservoir for P-TEFb
P-TEFb activity is ubiquitously regulated by interactions with
a set of protein and RNA regulators that are components of
a multisubunit complex called the 7SK small nuclear ribonucleo-
protein complex (snRNP) (Figure 4). Under normal growth condi-
tions, this complex serves as the primary reservoir of excess
cellular P-TEFb, which is released from this reservoir and bound
by the bromodomain-containing protein 4 (Brd4) when cells are
exposed to hypertrophic or stress signals (Zhou and Yik,
2006). The 7SK snRNP also contains 7SK snRNA, a conserved
small noncoding RNA produced by RNA Pol III, and nuclear
proteins HEXIM1 (or the homologous HEXIM2), La-related
protein 7 (LARP7), and 7SK-specific methyl-phosphate-capping
enzyme (MePCE). It sequesters more than half of cellular P-TEFb
in a catalytically inactive state (Figure 4). Inhibition of CDK9
kinase is caused by HEXIM1 by a still poorly defined process
that requires 7SK snRNA as a molecular scaffold to mediate
the interaction of P-TEFb with a homodimer of HEXIM1 (Michels
et al., 2004; Nguyen et al., 2001; Scho¨nichen et al., 2010; Yang
et al., 2001; Yik et al., 2003). The 50 end of 7SK snRNA is occu-
pied by MePCE and the 30 end by LARP7. This arrangement
protects the RNA against exonuclease cleavage (He et al.,
2008; Jeronimo et al., 2007). When bound by LARP7 in the
7SK snRNP, MePCE loses its capping activity, which effectively
prevents the back-reaction and plays a new role in stabilizing the
7SK snRNP (Xue et al., 2010).
Tat Extracts P-TEFb from Its Reservoir
Tat efficiently captures P-TEFb from the 7SK snRNP to increase
thepool of activeP-TEFbavailable forHIV transcription (Figure 4).
Consistent with this notion, HIV-1 infection of both human pri-
mary blood lymphocytes and cultured cells leads to decreased
cellular levels of 7SK snRNP and increased Tat/P-TEFb inter-
action (Barboric et al., 2007; Schulte et al., 2005; Sedore et al.,
2007). When Tat is present, it competes with Brd4 for P-TEFb
interaction, and Brd4 is rapidly dissociated from the HIV-1
template (Yang et al., 2005). The 7SK snRNP is an ideal source
for Tat to obtain P-TEFb, because it sequesters the majority of
cellular P-TEFb with the T-loop in CDK9 already in the phos-
phorylated state, a sign that P-TEFb is poised for activation
within this inactive complex (Chen et al., 2004; Li et al., 2005).
The precise mechanism used by Tat to extract P-TEFb from
the 7SK snRNP is not fully understood. Nevertheless, it is likelyCell Host & Microbe 10, Nfacilitated by a number of structural and
sequence similarities shared between
the 7SK snRNP and the Tat/TAR/P-TEFbcomplex (Zhou and Yik, 2006). For example, a portion of the
7SK snRNA that is normally contacted by HEXIM1 is structurally
and functionally similar to the Tat-binding site in HIV-1 TAR RNA
(Muniz et al., 2010). Moreover, the 7SK-binding domain in
HEXIM1 contains clusters of positively charged residues that
are reminiscent of the RNA-binding ARM in Tat (Yik et al.,
2004). Accordingly, Tat may use its RNA-binding ability to
directly replace HEXIM1 on the 7SK snRNA, thus causing the
disruption of 7SK snRNP and release of P-TEFb (Muniz et al.,
2010). It is unclear at this point how the interaction between
Tat and 7SK snRNA eventually transitions to the formation
of the Tat/TAR/P-TEFb-containing complex essential for Tat
transactivation. The recently described Tat-containing complex,
Tatcom2, which harbors CDK9, CycT1, and all the other classic
7SK snRNP components except HEXIM1, may well be a reaction
intermediate that is trapped during such a transition (Sobhian
et al., 2010).
Besides the RNA-binding motif, the cysteine-rich domain of
Tat is also important in extracting P-TEFb from the 7SK snRNP
(Barboric et al., 2007; Schulte et al., 2005; Sedore et al., 2007).
The high-affinity interaction of this domain with a small region
immediately C-terminal to the cyclin box in CycT1, which is
normally contacted by HEXIM1 with comparatively lower affinity,
allows Tat to directly displace HEXIM1 from CycT1 (Barboric
et al., 2007; Dames et al., 2007). The use of two separate
domains within Tat in the competition with HEXIM1 for binding
to P-TEFb could be a reason why Tat is so efficient in capturing
P-TEFb from the 7SK snRNP.
Tat may also enlist cellular cofactors to help disrupt the 7SK
snRNP. A candidate is protein phosphatase 1 (PP1), which
contributes to stress-induced 7SK snRNP disassembly by
dephosphorylating Thr186 at the CDK9 T-loop (Chen et al.,
2008). Since Tat binds PP1, it may recruit the phosphatase to
the 7SK snRNP to trigger its disruption (Ammosova et al.,
2005). In agreement with this model, inhibiting PP1 blocks Tat
transactivation and HIV-1 replication while enhancing cellular
levels of 7SK snRNP (Ammosova et al., 2011). However, Tat
engagement of PP1 during 7SK snRNP disruption will likely
release P-TEFb containing CDK9 with a dephosphorylated
T-loop and thereby in an inactive state. A subsequent rephos-
phorylation step would then be necessary to restore P-TEFb
kinase activity before its participation in Tat transactivation.
Although the vast majority of 7SK snRNP does not appear to
associate tightly with chromatin and is easily extracted fromovember 17, 2011 ª2011 Elsevier Inc. 431
Figure 5. Tat and the Super Elongation
Complex
Tat recruits the super elongation complex (SEC)
containing P-TEFb and ELL2, two well-known
elongation factors of different classes, to TAR
RNA. While P-TEFb phosphorylates the indicated
substrates, ELL2 stimulates the catalytic rate of
Pol II, resulting in synergistic activation of HIV-1
elongation. Tat stabilizes ELL2 levels to promote
SEC formation.
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components of this complex have been detected on the inte-
grated HIV-1 chromatin template (D’Orso and Frankel, 2010).
This observation and others led to amodel in which P-TEFb is re-
cruited as part of the 7SK snRNP to the HIV-1 preinitiation
complex with Tat and in which the synthesis of TAR triggers
the release of P-TEFb for activated transcription (D’Orso and
Frankel, 2010). While this is an attractive model, levels of 7SK
snRNP recruited to the HIV-1 LTR during basal transcription
appear to be low and cannot fully account for the high P-TEFb
concentration detected upon Tat activation (D’Orso and Frankel,
2010). This suggests that a combination of preloaded and exter-
nally recruited P-TEFb may be required for full Tat-mediated
transactivation.
Tat Employs a ‘‘Super Elongation Complex’’ to Activate
HIV-1 Transcription
After identification of CycT1 as the Tat cofactor, the question re-
mained whether Tat delivers the CycT1/CDK9 core complex
alone or in combination with other factors to the HIV-1 LTR to
activate transcription (Figure 1). To answer this question,
a sequential affinity-purification strategy was used to isolate
the complex that contains both CDK9 and Tat. This led to the
identification of transcription factors/cofactors ELL2, AFF4,
ENL, and AF9 as proteins associated with the Tat/P-TEFb
complex (Figure 5) (He et al., 2010). The same set of factors
plus several others (e.g., the AFF4 homolog AFF1, the ELL2
homolog ELL1, and components of the polymerase-associated
factor complex [PAFc]) were also isolated through affinity purifi-
cation of Tat alone (Sobhian et al., 2010). Furthermore, they were
independently identified to interact with P-TEFb and to be critical
in promoting the expression of genes targeted by the mixed-
lineage leukemia (MLL) protein (Lin et al., 2010; Mueller et al.,
2007, 2009; Yokoyama et al., 2010). These factors likely exist
in one or a few highly related multisubunit complex(es) termed432 Cell Host & Microbe 10, November 17, 2011 ª2011 Elsevier Inc.the superelongation complexes (SECs)
(He et al., 2010; Lin et al., 2010; Mueller
et al., 2009; Sobhian et al., 2010;
Yokoyama et al., 2010).
Like P-TEFb, the SEC subunits ELL1
and ELL2 are well-characterized tran-
scription elongation factors that stimulate
the processivity of Pol II by keeping the
30-OH of nascent mRNA in alignment
with the catalytic site and preventing Pol
II backtracking (Shilatifard et al., 1996,
1997). Thus, SECs combine two different
classes of elongation factors, P-TEFband ELL1 or ELL2, contradicting the presumption that these exist
as separate entities in cells. Tat recruits SEC to the HIV-1 LTR by
interacting with TAR RNA, enabling P-TEFb and ELL2 to act on
the same polymerase enzyme and synergistically activate tran-
scription (He et al., 2010; Sobhian et al., 2010). Tat also promotes
the SEC formation by stabilizing ELL2, which otherwise would be
a short-lived protein readily degraded by the proteasome
(Figure 5) (He et al., 2010).
Although SECs were identified as targets of MLL fusion
proteins and Tat, they also exist in cells free of Tat and MLL
translocations, where their activity is likely required for transcrip-
tion of many non-HIV, non-MLL target genes (He et al., 2010; Lin
et al., 2010; Sobhian et al., 2010). Interestingly, activation of
basal HIV transcription in the absence of Tat, an event essential
for reactivation of HIV transcription from latency, also depends
on SECs (He et al., 2010). Under such conditions, SECs interact
with PAFc and, through PAFc, the elongating Pol II to promote
HIV transcription (He et al., 2011). Notably, basal HIV-1 transcrip-
tion relies on Brd4 instead of Tat to recruit P-TEFb to the viral
promoter (Jang et al., 2005; Yang et al., 2005). The functional
relevance of this interaction is underscored by the finding that
the Brd4 gene represents a ‘‘hot spot’’ of proviral integration in
latently infected cells, where Brd4 expression is then disturbed
and HIV transcription silenced (Bisgrove et al., 2007). The func-
tional relationship between the Brd4-P-TEFb complex and
SECs is yet to be determined. It is possible that, once recruited
to the HIV LTR by Brd4, P-TEFb is released and then assembled
into SECs to support Tat-independent viral transcription.
Unanswered Questions
Although remarkable progress has been made in the past 13
years in understanding the function and regulation of cellular
P-TEFb and its intricate interactions with the viral Tat protein
and TAR RNA, many more questions have remained, and new
ones have been raised. These include the quest for a crystal
Cell Host & Microbe
Reviewstructure of the HIV-1 Tat/TAR/P-TEFb complex as an important
therapeutic target to tackle HIV infection. Similarly, structures of
both active and inactive P-TEFb complexes are yet to be solved
to provide mechanistic insights into how P-TEFb activity is
controlled in these complexes during active and latent viral
infection. Posttranslational modifications of Tat in the Tat/SEC
or Tatcom2 are not yet determined, and their roles in controlling
the formation, stability, and functions of the complexes remain to
be determined. The next few years will bring some answers to
these questions, which will open important new therapeutic
avenues to fight HIV infection and latency.ACKNOWLEDGMENTS
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